Claims
- 1. A method of treating cancer in a patient, said method comprising administering to said patient a compound having the formula: or a pharmaceutically acceptable salt thereof, in combination with a second approach to treatment.
- 2. The method of claim 1, wherein said second approach to treatment comprises administration of a chemotherapeutic drug to said patient.
- 3. The method of claim 2, wherein said chemotherapeutic drug is selected from the group consisting of antimetabolites, antibiotics, alkylating agents, plant alkaloids, and hormonal agents.
- 4. The method of claim 3, wherein said chemotherapeutic drug is an antimetabolite.
- 5. The method of claim 4, wherein said antimetabolite is gemcitabine.
- 6. The method of claim 5, wherein said cancer is non-small cell lung carcinoma, pancreatic cancer, or metastatic breast cancer.
- 7. The method of claim 4, wherein said antimetabolite is capecitabine.
- 8. The method of claim 7, wherein said cancer is breast cancer or colorectal cancer.
- 9. The method of claim 3, wherein said antibiotic is an anthracycline.
- 10. The method of claim 9, wherein said anthracycline is doxorubicin.
- 11. The method of claim 10, wherein said cancer is breast cancer.
- 12. The method of claim 3, wherein said chemotherapeutic drug is an alkylating agent.
- 13. The method of claim 12, wherein said alkylating agent is carboplatinum or cisplatinum.
- 14. The method of claim 13, wherein said cancer is non-small cell lung cancer or ovarian cancer.
- 15. The method of claim 3, wherein said chemotherapeutic drug is a plant alkaloid.
- 16. The method of claim 15, wherein said plant alkaloid is irinotecan.
- 17. The method of claim 16, wherein said cancer is colorectal cancer.
- 18. The method of claim 15, wherein said plant alkaloid is topotecan.
- 19. The method of claim 18, wherein said cancer is ovarian cancer or non-small cell lung cancer.
- 20. The method of claim 1, wherein said second approach to treatment comprises administration of an anticoagulant to said patient.
- 21. The method of claim 20, wherein said anticoagulant is heparin.
- 22. A composition comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, in combination with a second chemotherapeutic drug.
- 23. The composition of claim 22, wherein said chemotherapeutic drug is selected from the group consisting of antimetabolites, antibiotics, alkylating agents, plant alkaloids, and hormonal agents.
- 24. The composition of claim 23, wherein said chemotherapeutic drug is an antimetabolite.
- 25. The composition of claim 24, wherein said antimetabolite is gemcitabine.
- 26. The composition of claim 24, wherein said antimetabolite is capecitabine.
- 27. The composition of claim 23, wherein said antibiotic is an anthracycline.
- 28. The composition of claim 27, wherein said anthracycline is doxorubicin.
- 29. The composition of claim 23, wherein said chemotherapeutic drug is an alkylating agent.
- 30. The composition of claim 29, wherein said alkylating agent is carboplatinum or cisplatinum.
- 31. The composition of claim 23, wherein said chemotherapeutic drug is a plant alkaloid.
- 32. The composition of claim 31, wherein said plant alkaloid is irinotecan.
- 33. The composition of claim 31, wherein said plant alkaloid is topotecan.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of claims priority from U.S. Patent application Ser. No. 09/843,617, filed Apr. 26, 2001which is a continuation of U.S. Patent application Ser. No. 09/677,485, filed Oct. 2, 2000 (now U.S. Pat. No. 6,365,759), which is a continuation of U.S. Patent application Ser. No. 09/334,488, filed Jun. 16, 1999 (now U.S. Pat. No. 6,214,865), which claims priority from U.S. Provisional Patent Application Ser. No. 60/089,682, filed Jun. 17, 1998 (now abandoned). The contents of the earlier filed applications are incorporated by reference herein in their entirety.
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
5338865 |
Kishi et al. |
Aug 1994 |
A |
5436238 |
Kishi et al. |
Jul 1995 |
A |
6214865 |
Littlefield et al. |
Apr 2001 |
B1 |
6365759 |
Littlefield et al. |
Apr 2002 |
B1 |
6469182 |
Littlefield et al. |
Oct 2002 |
B1 |
Foreign Referenced Citations (2)
Number |
Date |
Country |
0 572 109 |
Dec 1993 |
EP |
WO 9317690 |
Sep 1993 |
WO |
Non-Patent Literature Citations (3)
Entry |
Aicher et al., “Total Synthesis of Halichondrin B and Norhalichondron B,” J. Am. Chem. Soc. 114:3162-3164 (1992). |
Horita et al., “Synthetic Studies of Halichondrin B, an Antitumor Polyether Macrolide Isolated from a Marine Sponge. 8. Synthesis of the Lactone Part (C1-C36) via Horner-Emmons Coupling Between C1-C15 and C16-C36 Fragments and Yamaguchi Lactonization,” Tetrahedron Letters 38:8965-8968 (1997). |
Stamos et al., “New Synthetic Route to the C.14-C.38 Segment of Halichondrins,” J. Org. Chem. 62:7552-7553 (1997). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/089682 |
Jun 1998 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09/677485 |
Oct 2000 |
US |
Child |
09/843617 |
|
US |
Parent |
09/334488 |
Jun 1999 |
US |
Child |
09/677485 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/843617 |
Apr 2001 |
US |
Child |
10/272167 |
|
US |